60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development...
The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island...
WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60...
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized...
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for...
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that...
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.